[{"question": "What is the main concern regarding the use of antithrombotic medications in patients receiving regional anesthesia?", "expected_output": "The heightened risk of neuraxial bleeding."}, {"question": "Which organizations collaborated to convene the Fourth Consensus Conference on Regional Anesthesia and Anticoagulation?", "expected_output": "The American Society of Regional Anesthesia and Pain Medicine (ASRA) and the European Society of Anaesthesiology (ESA)."}, {"question": "What type of patients does the guideline specifically address in relation to antithrombotic therapy?", "expected_output": "Parturients receiving antithrombotic therapy for the treatment and prevention of thromboembolism."}, {"question": "What significant risk was addressed for the first time in the 2010 consensus conference?", "expected_output": "The risk of significant bleeding in patients undergoing plexus and peripheral neural blockade."}, {"question": "What is the purpose of the guidelines developed by ASRA and other organizations?", "expected_output": "To provide recommendations for the management of patients undergoing neuraxial and peripheral regional anesthetic/analgesic blockade while on antithrombotic therapy."}, {"question": "What is the recommended time interval between the discontinuation of anticoagulants during therapeutic anticoagulation and subsequent neuraxial block?", "expected_output": "5 half-lives."}, {"question": "According to the FDA Drug Safety Communication, what is the recommended time interval between catheter removal and subsequent low-molecular-weight heparin (LMWH) administration?", "expected_output": "4 hours."}, {"question": "What is the classification level of evidence for recommendations derived from case reports or expert opinion?", "expected_output": "C level of evidence."}, {"question": "What percentage of hospitalized patients have at least one risk factor for venous thromboembolism?", "expected_output": "Nearly all hospitalized patients."}, {"question": "What is the significance of the time interval of 8 hours minus the time it takes for the anticoagulant to reach peak effect, as proposed by Rosencher et al?", "expected_output": "It determines the time to subsequent dosing following catheter manipulation."}, {"question": "What are the methods mentioned for achieving thromboprophylaxis?", "expected_output": "Compression stockings, intermittent compression devices, medications (chemoprophylaxis), or a combination of both."}, {"question": "What significant change did the AT9 guidelines introduce regarding the use of aspirin?", "expected_output": "The AT9 authors concluded that there is moderate-quality evidence supporting the use of aspirin in patients undergoing major orthopedic procedures, making it an option for thromboprophylaxis."}, {"question": "Who was the lead investigator for the AT9 guidelines?", "expected_output": "Gordon H. Guyatt."}, {"question": "What does the acronym ACCP stand for?", "expected_output": "American College of Chest Physicians."}, {"question": "According to the document, what is the risk level for which no specific prophylaxis is recommended?", "expected_output": "Very low risk (<0.5%)."}, {"question": "What are the indications for long-term anticoagulation with warfarin?", "expected_output": "Patients with a history of VTE, mechanical heart valves, and atrial fibrillation."}, {"question": "What is the recommended action for patients at high risk of thromboembolism regarding bridging therapy?", "expected_output": "Bridging therapy is recommended, typically with therapeutic SC LMWH or IV UFH."}, {"question": "What is the calculated incidence of spinal hematoma following epidural anesthetics?", "expected_output": "Less than 1 in 150,000 epidural anesthetics."}, {"question": "How long before elective surgery should warfarin be discontinued?", "expected_output": "At least 5 days before elective procedure."}, {"question": "What is the recommended timing for resuming antithrombotic therapy in patients at low risk of bleeding postoperatively?", "expected_output": "Initiate antithrombotic therapy 24 hours postoperatively."}, {"question": "How many patients had received intravenous or subcutaneous heparin?", "expected_output": "Twenty-five patients."}, {"question": "What percentage of patients experienced difficulty or bloody needle placement?", "expected_output": "25%."}, {"question": "What was the presenting symptom in 83% of cases related to spinal hematomas?", "expected_output": "Increased motor block."}, {"question": "What was the risk of spinal hematoma associated with epidural analgesia in women undergoing childbirth?", "expected_output": "1 in 200,000."}, {"question": "What is the action of plasmin in the fibrinolytic system?", "expected_output": "Dissolves intravascular clots."}, {"question": "How long after thrombolytic therapy are fibrinogen and plasminogen maximally depressed?", "expected_output": "5 hours."}, {"question": "What is the frequency of hemorrhagic events with streptokinase compared to t-PA therapy?", "expected_output": "The frequency of hemorrhagic events is similar."}, {"question": "What were the original contraindications to thrombolytic therapy?", "expected_output": "Surgery or puncture of noncompressible vessels within 10 days."}, {"question": "How many cases of spinal hematoma involving neuraxial anesthesia and thrombolytic therapy have been reported?", "expected_output": "6 cases."}, {"question": "What is recommended for patients who have received neuraxial blocks at or near the time of fibrinolytic therapy?", "expected_output": "Neurological monitoring should be continued for an appropriate interval, with checks not more than 2 hours apart."}, {"question": "What is suggested to evaluate the presence of residual thrombolytic effect in patients receiving neuraxial catheter infusion?", "expected_output": "The measurement of fibrinogen level."}, {"question": "What is the major anticoagulant effect of heparin attributed to?", "expected_output": "A unique pentasaccharide that binds to antithrombin."}, {"question": "How does the biologic half-life of heparin change with increasing doses?", "expected_output": "It increases from 30 minutes after 25 U/kg IV to 150 minutes with a bolus of 400 U/kg IV."}, {"question": "What anticoagulant monitoring test is typically used for therapeutic doses of heparin?", "expected_output": "The aPTT (activated partial thromboplastin time)."}, {"question": "What is the estimated incidence of spinal hematoma for traumatic spinal anesthesia with heparin?", "expected_output": "1:2900."}, {"question": "What is the associated factor in approximately 50% of spinal hematomas according to previous case reports?", "expected_output": "The presence of a bloody tap or a traumatic regional block."}, {"question": "What is the estimated risk of hematoma for epidural and spinal techniques as per Ho et al's mathematical analysis?", "expected_output": "Approximately 1:1528 for epidural and 1:3610 for spinal technique."}, {"question": "What should be done prior to neuraxial catheter manipulation or removal in patients who have undergone systemic heparinization?", "expected_output": "Heparin should be discontinued for 2 to 4 hours, and the coagulation status assessed."}, {"question": "What is the recommended action if a traumatic tap occurs during a neuraxial procedure?", "expected_output": "Surgery should be delayed 24 hours."}, {"question": "What is the common dosage of subcutaneous unfractionated heparin used for prophylaxis against VTE?", "expected_output": "5000 U of heparin subcutaneously twice daily (BID) or thrice daily (TID)."}, {"question": "What is the recommended action for patients receiving IV or SC UFH for more than 4 days before neuraxial block or catheter removal?", "expected_output": "Assess a platelet count."}, {"question": "What is the recommended time to discontinue heparin infusion before neuraxial blockade?", "expected_output": "4 to 6 hours."}, {"question": "What should be monitored postoperatively to detect motor blockade?", "expected_output": "The patient should be monitored for early detection of motor blockade."}, {"question": "What is the suggested time interval for removing indwelling neuraxial catheters after the last heparin dose?", "expected_output": "4 to 6 hours after the last heparin dose."}, {"question": "What is the recommended action if a bloody or difficult neuraxial needle placement occurs?", "expected_output": "Direct communication with the surgeon and a specific risk-benefit decision about proceeding in each case."}, {"question": "What is the suggested timing for neuraxial block after administering low-dose UFH?", "expected_output": "4 to 6 hours after heparin administration."}, {"question": "What is the recommended neuraxial block timing after administering higher-dose UFH?", "expected_output": "12 hours after SC heparin administration."}, {"question": "What is the elimination half-life of low-molecular-weight heparin (LMWH) in patients with normal renal function?", "expected_output": "3 to 6 hours after SC injection."}, {"question": "What is the risk of spinal hematoma estimated to be with continuous epidural anesthetics?", "expected_output": "Approximately 1 in 3000."}, {"question": "What should be assessed prior to neuraxial blockade when using LMWH?", "expected_output": "Anti-factor Xa activity."}, {"question": "What is the recommended prophylactic dose of enoxaparin for the prevention of deep vein thrombosis?", "expected_output": "30 mg BID or 40 mg once daily."}, {"question": "How long should a postprocedure dose of enoxaparin be given after catheter removal?", "expected_output": "No sooner than 4 hours after catheter removal."}, {"question": "What is the therapeutic dose of enoxaparin for bridging anticoagulation?", "expected_output": "1 mg/kg every 12 hours or 1.5 mg/kg daily."}, {"question": "What is the peak anti-factor Xa level range that should be maintained during high-dose LMWH bridging?", "expected_output": "Between 0.5 and 1 U/mL."}, {"question": "What factors are associated with an increased risk of spinal hematoma according to the document?", "expected_output": "Female sex, elderly age (\u226565 years), abnormalities of spinal cord or vertebral column, renal insufficiency, and traumatic needle/catheter placement."}, {"question": "What is the recommended delay for initiating LMWH therapy postoperatively after needle/catheter placement?", "expected_output": "The first dose of LMWH should be administered the following day and no earlier than 12 hours after needle/catheter placement."}, {"question": "What is the plasma half-life of fondaparinux?", "expected_output": "The plasma half-life of fondaparinux is 21 hours."}, {"question": "What should be assessed in patients receiving LMWH for more than 4 days before neuraxial block or catheter removal?", "expected_output": "A platelet count should be assessed."}, {"question": "What is the recommendation regarding the administration of medications affecting hemostasis when there is an indwelling neuraxial catheter?", "expected_output": "It is recommended against the concomitant administration of medications affecting hemostasis, such as antiplatelet drugs, standard heparin, or dextran."}, {"question": "How long should therapeutic-dose LMWH be delayed after high-bleeding-risk surgery?", "expected_output": "Therapeutic-dose LMWH may be resumed 48 to 72 hours after high-bleeding-risk surgery."}, {"question": "What are the names of the new oral anti-factor Xa agents mentioned in the document?", "expected_output": "Rivaroxaban, apixaban, edoxaban, and betrixaban."}, {"question": "What is the terminal elimination half-life of rivaroxaban in healthy patients?", "expected_output": "5 to 9 hours."}, {"question": "What is the recommended dose of apixaban for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation?", "expected_output": "5 mg BID."}, {"question": "How long after orthopedic surgery should rivaroxaban be started for the prevention of VTE?", "expected_output": "6 to 10 hours."}, {"question": "What should be avoided when using rivaroxaban in patients with a CrCl of less than 30 mL/min?", "expected_output": "Rivaroxaban should be avoided, except for patients with NV AF having a CrCl of 15 to 30 mL/min, where a dose reduction to 15 mg once daily applies."}, {"question": "What is the indication for Betrixaban?", "expected_output": "Prophylaxis of VTE in adult patients hospitalized for an acute medical illness who are at risk of thromboembolic complications."}, {"question": "What is the recommended dosing for Apixaban in patients with CrCl >50 mL/min?", "expected_output": "20 mg QD (European Union [EU], United States)."}, {"question": "What is the elimination half-life (t\u00bd\u03b2) of Rivaroxaban?", "expected_output": "5 \u20139 hours (young), 11\u2013 13 hours (elderly)."}, {"question": "What is the dosing for Edoxaban in patients with CrCl 15 \u201350 mL/min?", "expected_output": "15 mg QD (EU, United States)."}, {"question": "What is the renal clearance percentage for Apixaban?", "expected_output": "27%."}, {"question": "What is the recommended time interval between the last dose of prophylactic apixaban and neuraxial puncture?", "expected_output": "At least 26 to 30 hours."}, {"question": "What chromogenic assay is used to document the absence of apixaban activity?", "expected_output": "Chromogenic anti-factor Xa assay calibrated for apixaban."}, {"question": "What is the dosage of apixaban mentioned for patients that require a longer time interval before neuraxial procedures?", "expected_output": "5 mg/d."}, {"question": "What should be the time interval before administering the next dose of apixaban after neuraxial puncture?", "expected_output": "At least 6 hours."}, {"question": "What is the age threshold mentioned for patients requiring a longer time interval before neuraxial procedures?", "expected_output": "80 years or older."}, {"question": "What is the maximum plasma level time for Edoxaban after oral ingestion?", "expected_output": "1 to 2 hours."}, {"question": "What is the recommended dose of Edoxaban for the prevention of stroke and systemic embolism in patients with NVAF?", "expected_output": "60 mg once daily."}, {"question": "How much of the administered dose of Edoxaban is cleared by the kidney?", "expected_output": "Approximately 50%."}, {"question": "What is the terminal half-life of Betrixaban?", "expected_output": "37 hours."}, {"question": "What should be the time interval between the last dose of Betrixaban and neuraxial puncture?", "expected_output": "At least 72 hours."}, {"question": "What is the recommended dose of recombinant factor VIIa when used?", "expected_output": "90 \u03bcg/kg IV."}, {"question": "What are the two promising antidotes for factor Xa inhibitors mentioned in the document?", "expected_output": "PRT064445 (andexanet alfa) and PER977 (ciraparantag)."}, {"question": "How long should rivaroxaban be discontinued prior to a neuraxial block?", "expected_output": "72 hours."}, {"question": "What is the terminal elimination half-life of dabigatran after multiple doses in healthy patients?", "expected_output": "12 to 17 hours."}, {"question": "What is the recommendation regarding neuraxial techniques in patients receiving parenteral thrombin inhibitors?", "expected_output": "We recommend against the performance of neuraxial techniques."}, {"question": "What is the recommended dose of dabigatran for the prevention of recurrent VTE and PE in patients with CrCl >30 mL/min?", "expected_output": "150 mg BID."}, {"question": "What is the first oral dose of dabigatran given postoperatively for the prevention of VTE following orthopedic surgery?", "expected_output": "110 mg."}, {"question": "What is the elimination half-life of dabigatran in healthy patients?", "expected_output": "12 to 17 hours."}, {"question": "Which assay is best suited to monitor dabigatran levels?", "expected_output": "Thrombin time (TT) and dilute thrombin time (dTT)."}, {"question": "What is the FDA-approved antidote for reversing the anticoagulant effects of dabigatran?", "expected_output": "Idarucizumab."}, {"question": "What is the recommended dose of idarucizumab for rapid reversal of dabigatran's anticoagulant effects?", "expected_output": "5 g via an IV infusion/injection."}, {"question": "How long should dabigatran be discontinued prior to a neuraxial block in patients with a CrCl of 30 to 49 mL/min?", "expected_output": "120 hours."}, {"question": "What is the half-life of Factor VII?", "expected_output": "6 \u20138 hours."}, {"question": "Which patient characteristics are associated with increased sensitivity to warfarin?", "expected_output": "Age >65 years, female sex, weight <100 lb, liver, cardiac, or renal disease, Asian ancestry, excessive surgical blood loss."}, {"question": "What is the primary effect of warfarin as an oral anticoagulant?", "expected_output": "It interferes with the synthesis of the vitamin K-dependent clotting factors VII, IX, X, and II (thrombin)."}, {"question": "What anticoagulant is commonly used to bridge therapy when warfarin is stopped?", "expected_output": "LMWH (Low Molecular Weight Heparin)."}, {"question": "What was the incidence of major bleeding in the bridging group compared to the no-bridging group?", "expected_output": "3.2% in the bridging group versus 1.3% in the no-bridging group."}, {"question": "What is the recommended INR level for patients undergoing neuraxial procedures according to European and Scandinavian guidelines?", "expected_output": "An INR of 1.4 or lower."}, {"question": "What should be administered when there is life-threatening bleeding due to warfarin?", "expected_output": "Recombinant activated factor VIIa, 3-factor PCC, or 4-factor PCC."}, {"question": "How many patients were involved in the study that reported no spinal hematoma after neuraxial block with low-dose warfarin therapy?", "expected_output": "More than 600 patients."}, {"question": "What is the recommendation regarding the concurrent use of medications that affect clotting mechanisms for patients receiving oral anticoagulants?", "expected_output": "We recommend against the concurrent use of medications that affect other components of the clotting mechanisms and may increase the risk of bleeding complications."}, {"question": "What should be checked prior to neuraxial block in patients receiving an initial dose of warfarin before surgery?", "expected_output": "The INR should be checked prior to neuraxial block if the first dose was given more than 24 hours earlier or a second dose of oral anticoagulant has been administered."}, {"question": "What is suggested for patients receiving low-dose warfarin therapy during epidural analgesia?", "expected_output": "It is suggested that their INR be monitored on a daily basis."}, {"question": "What is the recommended INR threshold for removing neuraxial catheters when thromboprophylaxis with warfarin is initiated?", "expected_output": "Neuraxial catheters should be removed when the INR is less than 1.5."}, {"question": "What are the three thienopyridine derivatives mentioned in the document?", "expected_output": "The three thienopyridine derivatives are ticlopidine, clopidogrel, and prasugrel."}, {"question": "What is the black box warning associated with ticlopidine?", "expected_output": "Thrombocytopenic purpura and aplastic anemia."}, {"question": "How long should ticlopidine be discontinued before an elective procedure?", "expected_output": "10 to 14 days."}, {"question": "What is the recommended discontinuation period for clopidogrel before surgery?", "expected_output": "5 days."}, {"question": "What is the onset time for the antiplatelet effect of ticagrelor after a loading dose?", "expected_output": "Within 30 minutes."}, {"question": "What is the dosage for cangrelor when used as an adjunct to PCI?", "expected_output": "30-\u03bcg/kg bolus followed by an infusion of 4 \u03bcg/kg per minute."}, {"question": "What is the terminal half-life of dipyridamole?", "expected_output": "10 hours."}, {"question": "How long should a time interval be maintained after the last dose of cilostazol before neuraxial blockade?", "expected_output": "42 hours."}, {"question": "What combination of medications is associated with more bleeding complications than clopidogrel?", "expected_output": "Aspirin and extended-release dipyridamole."}, {"question": "What was the conclusion regarding NSAIDs and the risk of spinal-epidural hematomas?", "expected_output": "NSAIDs did not appear to present significant risk to patients for developing spinal-epidural hematomas."}, {"question": "What should be considered in patients requiring anti-inflammatory therapy in the presence of anticoagulation?", "expected_output": "Cyclooxygenase 2 inhibitors."}, {"question": "What is the recommended time interval for discontinuation of ticlopidine therapy before neuraxial blockade?", "expected_output": "10 days."}, {"question": "How long after surgery can thienopyridine therapy be reinstituted according to ACCP recommendations?", "expected_output": "24 hours postoperatively."}, {"question": "What is the suggested time interval for resuming ticagrelor therapy after needle placement or catheter removal?", "expected_output": "Immediately, provided a loading dose is not administered."}, {"question": "What is the elimination half-life recommendation for avoiding neuraxial techniques after discontinuation of cilostazol?", "expected_output": "2 days."}, {"question": "What potential complication is associated with the use of herbal medications in surgical patients?", "expected_output": "Bleeding from garlic, ginkgo, and ginseng."}, {"question": "What is the recommended action regarding herbal medications before surgery?", "expected_output": "It is not deemed necessary to discontinue herbal medications prior to surgery or anesthesia."}, {"question": "What is the incidence of spinal hematoma after neuraxial blockade in obstetric patients?", "expected_output": "The document does not specify the exact incidence of spinal hematoma after neuraxial blockade."}, {"question": "What are common risk factors that increase the incidence of thrombosis in pregnant women?", "expected_output": "Common risk factors include increasing age, prolonged immobilization, obesity, thrombophilia, previous thromboembolism, and cesarean delivery."}, {"question": "How long does it take for garlic to normalize hemostasis after discontinuation?", "expected_output": "7 days."}, {"question": "What does the NPMS Consensus Bundle advocate for in relation to obstetric thromboembolism?", "expected_output": "It advocates for more aggressive risk-based assessment of obstetric patients."}, {"question": "What is the reported incidence of spinal hematoma after obstetric epidural blockade according to Moen et al?", "expected_output": "1:200,000."}, {"question": "How many epidural hematomas were reported among the 142,287 patients undergoing epidural anesthesia/analgesia?", "expected_output": "7 epidural hematomas."}, {"question": "What is the overall risk of developing a spinal hematoma for perioperative patients undergoing epidural catheter placement?", "expected_output": "1:9000."}, {"question": "What protective factor is suggested to contribute to the lower rate of neuraxial hematomas in obstetric patients?", "expected_output": "The relatively hypercoagulable state of pregnancy."}, {"question": "What are the recommended anticoagulant therapy measures for obstetric patients upon the onset of labor according to the ACCP and NPMS?", "expected_output": "Discontinuing anticoagulant therapy upon the onset of labor."}, {"question": "What year was the study by Ballin published?", "expected_output": "1981"}, {"question": "What was the outcome for the patient in the study by Yuen et al in 1999?", "expected_output": "Recovered"}, {"question": "Which technique was used in all studies listed in Table 17?", "expected_output": "Epidural"}, {"question": "What condition was associated with the patient in the study by Lao et al in 1993?", "expected_output": "Preeclampsia and lupus anticoagulant"}, {"question": "What surgical treatment was performed for the patient in the study by Chiaghana et al in 2016?", "expected_output": "Decompressive laminectomy"}, {"question": "What factors should be weighed when choosing analgesia and/or anesthesia in anticoagulated patients?", "expected_output": "The risks of general anesthesia and benefits of neuraxial anesthesia, considering the anticoagulant type, dose, time of administration, and pertinent laboratory values."}, {"question": "When can prophylactic LMWH be started or restarted postpartum?", "expected_output": "6 to 12 hours after delivery and no sooner than 4 hours after epidural catheter removal, whichever is later."}, {"question": "What is the recommendation regarding the application of ASRA guidelines to parturients?", "expected_output": "The ASRA guidelines should be applied to parturients (grade 2C)."}, {"question": "What is the most significant hemorrhagic complication of regional anesthesia mentioned in the document?", "expected_output": "Spinal hematoma."}, {"question": "How many cases of hemorrhagic complications associated with peripheral or plexus block in patients receiving antithrombotic therapy are reported?", "expected_output": "18 cases."}, {"question": "What organizations collaborated to construct a single set of guidelines for thromboembolism prophylaxis and regional anesthesia?", "expected_output": "ESA and ASRA."}, {"question": "What is the recommended INR level for patients receiving warfarin according to ASRA guidelines before neuraxial block?", "expected_output": "A normal INR."}, {"question": "What is the primary anticoagulant recommended for pregnant patients during antepartum management?", "expected_output": "Heparin compounds."}, {"question": "How long should neuraxial blockade be withheld after the last prophylactic dose of LMWH?", "expected_output": "10 \u2013 12 hours."}, {"question": "What is the purpose of the 'pharmacy failsafe' mentioned in the document?", "expected_output": "To alert pharmacists of potential drug interactions and ensure safe management of patients receiving epidural infusions."}, {"question": "What type of block did the 59-year-old woman undergo in the case reported by Wheatley et al.?", "expected_output": "Lumbar sympathetic blocks."}, {"question": "What was the outcome of the patient treated by Kurzel et al. after the bilateral pudendal block?", "expected_output": "The patient was treated with broad-spectrum antibiotics and dismissed after 3 days when fever and pain resolved."}, {"question": "How much blood was evacuated during the surgical intervention for the patient in the case reported by Wheatley et al.?", "expected_output": "1000 mL of blood."}, {"question": "What complication did the 62-year-old woman experience after the sequential stellate ganglion blocks according to Mishio et al.?", "expected_output": "Massive hemorrhage from clivus to the diaphragm."}, {"question": "What was the size of the hematoma developed by the patient in the case reported by Stan et al.?", "expected_output": "Small (<2 cm) hematoma."}, {"question": "What was the main purpose of the survey conducted at the 11th Annual ASRA Pain Medicine Meeting?", "expected_output": "To determine practice patterns of pain physicians regarding the use of anticoagulants and antiplatelet agents during interventional pain procedures."}, {"question": "What percentage of respondents followed ASRA guidelines for anticoagulants?", "expected_output": "Most of the respondents followed ASRA guidelines for anticoagulants."}, {"question": "What specific medication did 55% of participants stop before spinal cord stimulation trials and implants?", "expected_output": "Acetylsalicylic acid (aspirin)."}, {"question": "According to the document, what risk may have been underestimated in patients undergoing interventional pain procedures?", "expected_output": "The risk of significant bleeding."}, {"question": "What did the ASRA guidelines state regarding the discontinuation of aspirin or NSAIDs prior to epidural and spinal block placement?", "expected_output": "The guidelines do not recommend discontinuation of aspirin or NSAIDs prior to the placement of epidural and spinal blocks."}, {"question": "What anticoagulant was used preoperatively in the case of the 80-year-old man described in the document?", "expected_output": "Warfarin."}, {"question": "What was the size of the hematoma that developed in the 80-year-old man after the intercostal nerve blocks?", "expected_output": "30 \u00d7 65 cm."}, {"question": "In the case of the 71-year-old woman, what was the initial treatment for her low back pain after the lumbar plexus block?", "expected_output": "Mephenamic acid (NSAID)."}, {"question": "What imaging techniques were used to reveal the renal subcapsular hematoma in the 68-year-old woman?", "expected_output": "CT scan and ultrasonography."}, {"question": "What was the postoperative treatment regimen for the 67-year-old woman after her sciatic block?", "expected_output": "Enoxaparin 30 mg BID and aspirin 325 mg/d."}, {"question": "What was the age of the woman in the case reported by Maier et al. in 2002?", "expected_output": "79 years old."}, {"question": "What anticoagulant was the 71-year-old man taking before the lumbar sympathetic block?", "expected_output": "Ticlopidine 500 mg/d."}, {"question": "What significant complication did the 85-year-old woman experience postoperatively according to Weller et al.?", "expected_output": "Extensive retroperitoneal hematoma."}, {"question": "How much enoxaparin was administered to the 85-year-old woman on POD2?", "expected_output": "30 mg."}, {"question": "What was the outcome for the 79-year-old woman after the lumbar sympathetic block?", "expected_output": "She was found pulseless and resuscitation attempts were unsuccessful."}, {"question": "What was the age and gender of the patient in the study by Weller et al.?", "expected_output": "65-y-old man."}, {"question": "What anticoagulant was the patient in Weller et al.'s study taking preoperatively?", "expected_output": "Warfarin 5 mg/d."}, {"question": "What complication did the 72-y-old woman in Aveline et al.'s study experience postoperatively?", "expected_output": "Progressive left leg motor deficit and left lumbar back pain."}, {"question": "What was the INR level of the patient in Aveline et al.'s study when extensive ecchymosis was noted?", "expected_output": "INR 3.5."}, {"question": "What was the outcome for the patient in Bickler et al.'s study after the removal of nerve catheters?", "expected_output": "Swelling and discoloration were noted at both the femoral and sciatic insertion sites."}, {"question": "What was the age of the woman who underwent total knee replacement and had a continuous sciatic nerve catheter placed?", "expected_output": "78 years old."}, {"question": "What anticoagulant medication was administered on POD1 to the patients in the study?", "expected_output": "Enoxaparin 40 mg/d subcutaneously."}, {"question": "What complication did the patient in the study by Wiegel et al experience on POD6?", "expected_output": "A retroperitoneal hematoma that required surgical intervention."}, {"question": "What was the outcome for the 66-year-old woman who had a continuous interscalene block and developed a hematoma?", "expected_output": "She was admitted with sepsis and discharged after a 30-day hospital stay in good condition."}, {"question": "What was the result of the cultures taken from the patient who developed signs of infection after the interscalene catheter placement?", "expected_output": "Cultures revealed Staphylococcus aureus."}, {"question": "What was the age and gender of the patient in the Rodriguez et al study?", "expected_output": "59-year-old woman."}, {"question": "What complication did the patient in the Rodriguez et al study experience 10 days postoperatively?", "expected_output": "A large, soft hematoma at the proximal two-thirds of the thigh that extended to the knee."}, {"question": "What was the size of the retroperitoneal hematoma found in the Parvaiz et al study?", "expected_output": "22 \u00d7 10 \u00d7 7 cm."}, {"question": "What anticoagulant was the 87-year-old man in the Warner et al study taking preoperatively?", "expected_output": "Aspirin 325 mg BID."}, {"question": "What was the hemoglobin level of the patient in the Warner et al study in the postanesthesia care unit?", "expected_output": "5.2 g/dL."}, {"question": "What organization endorsed the committee that developed guidelines for pain interventions?", "expected_output": "The European Society of Regional Anaesthesia & Pain Therapy."}, {"question": "What are the three categories used to stratify bleeding risk according to the document?", "expected_output": "Mild, intermediate, and high bleeding risks."}, {"question": "What is the recommended interval for discontinuing NSAIDs before a medium- or high-risk procedure?", "expected_output": "An interval of 5 half-lives of the NSAID."}, {"question": "What type of procedures are classified as high-risk according to the ASRA pain guidelines?", "expected_output": "Spinal cord stimulator placements and intrathecal pump placements."}, {"question": "How long should aspirin be discontinued for primary prevention before a procedure?", "expected_output": "6 days."}, {"question": "What is the recommended interval between administration of the drug and neuraxial injection according to the document?", "expected_output": "4 to 6 hours."}, {"question": "How many half-lives of the new direct oral anticoagulants should pass before a regional or pain intervention?", "expected_output": "5 half-lives."}, {"question": "What is the recommended interval for resumption of the drug after a neuraxial procedure according to the ASRA regional guidelines?", "expected_output": "6 hours."}, {"question": "What is the maximum recommended time for initiation of thromboprophylaxis with new oral anticoagulants after a surgical procedure?", "expected_output": "72 hours."}, {"question": "What do the practice guidelines or recommendations summarize according to the document?", "expected_output": "Evidence-based reviews."}, {"question": "What is the risk associated with the removal of indwelling catheters in patients receiving therapeutic anticoagulation?", "expected_output": "It significantly increases the risk of spinal hematoma."}, {"question": "What percentage of patients in Vandermeulen and colleagues' series had no identifiable risk factor for spinal hematoma?", "expected_output": "13%."}, {"question": "Who are the authors acknowledged for their collaboration on the management of the obstetric patient receiving antithrombotic therapy?", "expected_output": "Lisa Leffert, Ruth Landau, Alex Butwick, and Brendan Carvalho."}, {"question": "What must be optimized at the time of spinal or epidural needle/catheter placement?", "expected_output": "The patient's coagulation status."}, {"question": "What protocols must be in place if there is a change in neurologic status?", "expected_output": "Protocols for urgent MRI and hematoma evacuation."}, {"question": "What is the title of the guidelines published by the American College of Chest Physicians in 2012 regarding the prevention of VTE in nonorthopedic surgical patients?", "expected_output": "Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed."}, {"question": "In which year was the 8th edition of the American College of Chest Physicians evidence-based clinical practice guidelines published?", "expected_output": "2008"}, {"question": "What is the focus of the guidelines authored by Douketis JD and colleagues in 2012?", "expected_output": "Perioperative management of antithrombotic therapy."}, {"question": "Which publication contains the guidelines on antiplatelet drugs as part of the 9th edition of the American College of Chest Physicians evidence-based clinical practice guidelines?", "expected_output": "Chest."}, {"question": "What complication is associated with thrombolytic therapy as discussed in the document?", "expected_output": "Spinal epidural hematoma."}, {"question": "What is the title of the document authored by Toyonaga M and colleagues?", "expected_output": "Acute cervical spinal epidural hematoma during antithrombotic therapy: dual warnings against antithrombotic therapy [in Japanese]."}, {"question": "In which journal was the article by Gupta K et al. published?", "expected_output": "J Cardiovasc Dis Res."}, {"question": "What year was the article by Hirsh J et al. on parenteral anticoagulants published?", "expected_output": "2008."}, {"question": "What complication is associated with epidural anesthesia according to Wulf H?", "expected_output": "Spinal haematoma."}, {"question": "Which anticoagulant is mentioned in the title of the article by Vandiver JW and Vondracek TG?", "expected_output": "Unfractionated heparin."}, {"question": "What is the main focus of the study conducted by the EXPERT Study Investigators?", "expected_output": "The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb."}, {"question": "Which medication is discussed in relation to renal impairment and its dosing?", "expected_output": "Enoxaparin."}, {"question": "What is the publication year of the study that evaluates the pharmacokinetics and safety of rivaroxaban in chronic hemodialysis?", "expected_output": "2016."}, {"question": "What type of drug is betrixaban classified as?", "expected_output": "An oral factor Xa inhibitor."}, {"question": "Which study investigates the effects of renal function on edoxaban pharmacokinetics?", "expected_output": "The study by Ridout G, de la Motte S, Niemezyk S, et al."}, {"question": "What is the title of the study referenced in the document that involves Factor Xa in atrial fibrillation?", "expected_output": "Factor Xa Next Generation in Atrial Fibrillation \u2014Thrombolysis in Myocardial Infarction Study 48 (ENGAGE AF-TIMI 48)."}, {"question": "In which year was the study on the short-term safety and plasma concentrations of edoxaban in Japanese patients published?", "expected_output": "2015."}, {"question": "What is the primary focus of the randomized, multicenter, warfarin-controlled phase II study mentioned in the document?", "expected_output": "The study focuses on edoxaban in Japanese patients with non-valvular atrial fibrillation."}, {"question": "What is the main subject of the article by Douxfils et al. published in 2015?", "expected_output": "The impact of edoxaban on routine and specific coagulation assays."}, {"question": "Which specific antidote is mentioned for the reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa?", "expected_output": "A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa."}, {"question": "What is the title of the study conducted by Eriksson BI et al. comparing dabigatran etexilate with enoxaparin?", "expected_output": "A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial."}, {"question": "In which year was the study on the measurement of dabigatran in clinical assays published?", "expected_output": "2014."}, {"question": "What is the main focus of the study by Schiele et al. regarding dabigatran?", "expected_output": "A specific antidote for dabigatran: functional and structural characterization."}, {"question": "Which anticoagulant is compared to warfarin in the study by Kimmel SE et al.?", "expected_output": "A pharmacogenetic versus a clinical algorithm for warfarin dosing."}, {"question": "What was the outcome of the study by Liu SS et al. regarding the removal of epidural catheters?", "expected_output": "Uncomplicated removal of epidural catheters in 4365 patients with international normalized ratio greater than 1.4 during initiation of warfarin therapy."}, {"question": "What year was the study on aspirin and bleeding-time published in The Lancet?", "expected_output": "1979"}, {"question": "Which medication was associated with spontaneous spinal epidural hematoma in a patient with ankylosing spondylitis after total hip replacement?", "expected_output": "Aspirin"}, {"question": "What is the title of the guidelines published by the American College of Chest Physicians regarding antiplatelet drugs?", "expected_output": "Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)"}, {"question": "In which journal was the randomized controlled trial on the effects of celecoxib on platelet function published?", "expected_output": "Journal of Clinical Pharmacology"}, {"question": "What was the focus of the study conducted by the CLASP collaborative group?", "expected_output": "The prevention and treatment of pre-eclampsia among pregnant women using low-dose aspirin."}, {"question": "What is the title of the article authored by Palmerola et al. in 2016?", "expected_output": "A comparison of recommendations for pharmacologic thromboembolism prophylaxis after caesarean delivery from three major guidelines."}, {"question": "Which journal published the article by Ansari et al. in 2016?", "expected_output": "Anesth Analg."}, {"question": "What year was the article by Bateman et al. regarding epidural hematomas published?", "expected_output": "2012."}, {"question": "What is the main focus of the article by Sibai et al. published in 1986?", "expected_output": "Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia."}, {"question": "Which study discusses the effectiveness and safety of postoperative pain management?", "expected_output": "Effectiveness and safety of postoperative pain management: a survey of 18 925 consecutive patients between 1998 and 2006 (2nd revision): a database analysis of prospectively raised data."}, {"question": "What is the title of the case report authored by Rodriguez et al.?", "expected_output": "Intraneural hematoma after nerve stimulation \u2013guided femoral block in a patient with factor XI deficiency: case report."}, {"question": "In which year was the study on the incidence of hematoma formation following total knee arthroplasty published?", "expected_output": "2014."}, {"question": "What complication is associated with the lumbar sympathetic nerve block as mentioned in the document?", "expected_output": "Massive subcapsular hematoma."}, {"question": "Which anticoagulant is mentioned in relation to bleeding after intercostal nerve block?", "expected_output": "Heparin."}, {"question": "What is the focus of the study by Douketis et al. published in 2016?", "expected_output": "Periprocedural management of direct oral anticoagulants."}, {"question": "What is the title of the guideline discussed in the document?", "expected_output": "2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery"}, {"question": "In what year was the document approved by the American College of Cardiology Board of Trustees and the American Heart Association Science Advisory and Coordinating Committee?", "expected_output": "July 2014"}, {"question": "Who is the chair of the writing committee for the guideline?", "expected_output": "Lee A. Fleisher, MD, FACC, FAHA"}, {"question": "Which organizations collaborated in the development of the guideline?", "expected_output": "American College of Surgeons, American Society of Anesthesiologists, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Anesthesiologists, and Society of Vascular Medicine"}, {"question": "Where can the online-only Comprehensive Relationships Data Supplement be accessed?", "expected_output": "http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000106/-/DC1"}, {"question": "What is the title of the guideline authored by Fleisher et al. in 2014?", "expected_output": "ACC/AHA Perioperative Guideline"}, {"question": "What section of the document discusses the definitions of urgency and risk?", "expected_output": "1.5. Definitions of Urgency and Risk"}, {"question": "Which clinical risk factor is addressed in section 2.2 of the document?", "expected_output": "Heart Failure"}, {"question": "What is the focus of section 3 in the document?", "expected_output": "Calculation of Risk to Predict Perioperative Cardiac Morbidity"}, {"question": "Who is the chair of the ACC/AHA task force members listed in the document?", "expected_output": "Jeffrey L. Anderson, MD, FACC, FAHA"}, {"question": "What organizations are committed to the prevention and management of cardiovascular diseases according to the document?", "expected_output": "The American College of Cardiology (ACC) and the American Heart Association (AHA)."}, {"question": "What is the target cycle planned for full revision of the clinical practice guidelines (CPGs)?", "expected_output": "5 years."}, {"question": "What does GDMT stand for in the context of the document?", "expected_output": "Guideline-Directed Medical Therapy."}, {"question": "What type of studies does the guideline writing committee (GWC) focus on during literature searches?", "expected_output": "Randomized controlled trials (RCTs)."}, {"question": "What is the purpose of the Evidence Review Committees (ERCs) as mentioned in the document?", "expected_output": "To address key clinical questions posed in the PICOTS format."}, {"question": "What is the main effort of the Task Force regarding conflicts of interest?", "expected_output": "To avoid actual, potential, or perceived conflicts of interest that might arise through relationships with industry or other entities."}, {"question": "What is required from GWC members and reviewers concerning industry relationships?", "expected_output": "They are required to fully disclose current industry relationships or personal interests from 12 months before the initiation of the writing effort."}, {"question": "What does GWC stand for in the context of the document?", "expected_output": "Guideline Writing Committee."}, {"question": "Where can comprehensive disclosure information for the Task Force be found?", "expected_output": "At http://www.cardiosource.org/en/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-and-Documents-Task-Forces.aspx."}, {"question": "What does a recommendation with Level of Evidence B or C imply according to the document?", "expected_output": "It does not imply that the recommendation is weak; many important key clinical questions addressed in the guidelines do not lend themselves to clinical trials."}, {"question": "What is the main focus of the CPG described in the document?", "expected_output": "The perioperative cardiovascular evaluation and management of the adult patient undergoing noncardiac surgery."}, {"question": "What methodology was used for the evidence review conducted in April 2013?", "expected_output": "An extensive literature review through July 2013, including selected references published through May 2014."}, {"question": "Who is the chair of the ACC/AHA Task Force on Practice Guidelines?", "expected_output": "Jeffrey L. Anderson, MD, FACC, FAHA."}, {"question": "What does CPG stand for in the context of this document?", "expected_output": "Clinical Practice Guidelines."}, {"question": "Which organizations endorsed the recommendations in this CPG?", "expected_output": "The American College of Surgeons, American Society of Anesthesiologists, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Anesthesiologists, Society of Hospital Medicine, and Society of Vascular Medicine."}, {"question": "What is the goal of preoperative evaluation as described in the document?", "expected_output": "To promote patient engagement and facilitate shared decision making by providing patients and their providers with clear, understandable information about perioperative cardiovascular risk in the context of the overall risk of surgery."}, {"question": "What is the definition of an emergency procedure according to the document?", "expected_output": "An emergency procedure is one in which life or limb is threatened if not in the operating room, typically within <6 hours, with time for no or very limited clinical evaluation."}, {"question": "What percentage of patients had an isolated peak troponin T value of \u22650.02 ng/mL in the study mentioned?", "expected_output": "11.6% of patients."}, {"question": "What is the 30-day mortality rate for patients with elevated troponin T values in the study referenced?", "expected_output": "1.9% (95% confidence interval [CI]: 1.7% to 2.1%)."}, {"question": "What framework did the Task Force develop regarding the DECREASE trials?", "expected_output": "The ERC will include the DECREASE trials in the sensitivity analysis, but the systematic review report will be based on the published data on perioperative beta blockade, with data from all DECREASE trials excluded."}, {"question": "What is the recommended time frame to wait after a myocardial infarction (MI) before undergoing noncardiac surgery in the absence of a coronary intervention?", "expected_output": "At least 60 days."}, {"question": "What is the independent risk factor for perioperative stroke associated with a recent MI?", "expected_output": "Having a recent MI within 6 months of non-cardiac surgery."}, {"question": "What percentage of postoperative myocardial infarction (MI) occurs within 0 to 30 days after a recent MI?", "expected_output": "32.8%."}, {"question": "Which age group has a higher reported incidence of acute ischemic stroke during noncardiac surgery?", "expected_output": "Older adult patients (those >65 years of age)."}, {"question": "What is the impact of age >62 years on perioperative stroke risk?", "expected_output": "It is an independent risk factor for perioperative stroke."}, {"question": "What is the age threshold mentioned in the document for older adults at risk for perioperative complications?", "expected_output": "Older adults >70 years of age."}, {"question": "What is the significance of a history of cerebrovascular disease according to the document?", "expected_output": "It has been shown to predict perioperative MACE."}, {"question": "What are the independent prognostic variables included in widely used indices of cardiac risk for patients with heart failure?", "expected_output": "The presence of preoperative third heart sound and jugular venous distention."}, {"question": "What is the 30-day postoperative mortality rate for patients with nonischemic heart failure as stated in the document?", "expected_output": "9.3%."}, {"question": "According to the document, what is the risk-adjusted 30-day mortality and readmission rate in patients with heart failure compared to an elderly control group without a history of CAD or HF?", "expected_output": "50% to 100% higher."}, {"question": "What do preoperative natriuretic peptide levels predict?", "expected_output": "Cardiovascular events in the first 30 days after vascular surgery."}, {"question": "What is the incidence of peripartum cardiomyopathy during deliveries?", "expected_output": "Approximately 1 in 1000 deliveries."}, {"question": "What is a major concern for patients with peripartum cardiomyopathy during surgery?", "expected_output": "To optimize fluid administration and avoid myocardial depression while maintaining stable intraoperative hemodynamics."}, {"question": "What is recommended for patients with clinically suspected moderate or greater degrees of valvular stenosis or regurgitation?", "expected_output": "They should undergo preoperative echocardiography if there has been no prior echocardiography within 1 year or a significant change in clinical status since the last evaluation."}, {"question": "What percentage of sudden death cases associated with arrhythmogenic RV cardiomyopathy occurred during the perioperative period according to the autopsy study?", "expected_output": "9.5% of cases."}, {"question": "What is the perioperative mortality rate associated with severe aortic stenosis compared to patients without aortic stenosis?", "expected_output": "The perioperative mortality rate for severe aortic stenosis is 13%, compared to 1.6% in patients without aortic stenosis."}, {"question": "What is the recommended approach for patients with asymptomatic severe aortic stenosis undergoing elevated-risk elective noncardiac surgery?", "expected_output": "Elevated-risk elective noncardiac surgery with appropriate intraoperative and postoperative hemodynamic monitoring is reasonable."}, {"question": "What is the 30-day mortality rate for patients with moderate aortic stenosis undergoing nonemergency noncardiac surgery?", "expected_output": "The 30-day mortality rate for patients with moderate aortic stenosis is 2.1%."}, {"question": "What are the predictors of 30-day death and postoperative myocardial infarction in patients with moderate or severe aortic stenosis?", "expected_output": "Predictors include high-risk surgery (OR: 7.3), symptomatic severe aortic stenosis (OR: 2.7), coexisting moderate or severe mitral regurgitation (OR: 9.8), and pre-existing coronary artery disease (OR: 2.7)."}, {"question": "What is the 1-year mortality rate for transcatheter aortic valve replacement compared to standard therapy for patients not eligible for surgical aortic valve replacement?", "expected_output": "The 1-year mortality rate for transcatheter aortic valve replacement is 30.7%, compared to 50.7% for standard therapy."}, {"question": "What was the postoperative morbidity rate for patients with moderate-to-severe AR compared to case-matched controls without AR?", "expected_output": "16.2% versus 5.4%; P=0.003."}, {"question": "What are some predictors of in-hospital death mentioned in the document?", "expected_output": "Depressed LVEF (EF <55%), renal dysfunction (creatinine >2 mg/dL), high surgical risk, and lack of preoperative cardiac medications."}, {"question": "What was the 30-day mortality rate for patients with moderate-to-severe MR undergoing nonemergency non-cardiac surgery compared to controls without MR?", "expected_output": "1.7% versus 1.1%; P=0.43."}, {"question": "What is the most common sustained tachyarrhythmia mentioned in the document?", "expected_output": "Atrial fibrillation (AF)."}, {"question": "What should be considered if a patient with persistent AF undergoes surgery involving physical manipulation of the heart?", "expected_output": "The potential for perioperative formation of left atrial thrombus."}, {"question": "What is the main recommendation regarding the perioperative management of patients with CIEDs?", "expected_output": "The perioperative management of patients with CIEDs must be individualized, and a single recommendation for all patients with CIEDs is not appropriate."}, {"question": "What should the surgical/procedure team communicate to the CIED clinician/team?", "expected_output": "The nature of the planned procedure and the type of electromagnetic interference (EMI) likely to be encountered."}, {"question": "How often should patients with pacemakers be evaluated according to the document?", "expected_output": "At least annually."}, {"question": "What is the mortality rate range for patients with pulmonary hypertension undergoing noncardiac surgery?", "expected_output": "4% to 26%."}, {"question": "What is recommended for patients with adult congenital heart disease (ACHD) before surgery?", "expected_output": "It is optimal to perform the preoperative evaluation in a regional center specializing in congenital cardiology."}, {"question": "What does RCRI stand for in the context of the document?", "expected_output": "Revised Cardiac Risk Index."}, {"question": "What is one of the criteria used by the American College of Surgeons NSQIP Surgical Risk Calculator?", "expected_output": "Acute renal failure."}, {"question": "How many types of surgeries are listed under the American College of Surgeons NSQIP MICA?", "expected_output": "At least 14 types of surgeries."}, {"question": "What is the significance of 'Increasing age' in the RCRI criteria?", "expected_output": "It is one of the factors that increases the risk assessment for patients."}, {"question": "According to the document, how does the use of the RCRI differ from the American College of Surgeons NSQIP MICA?", "expected_output": "The RCRI allows use outside the original cohort, while the NSQIP MICA does not."}, {"question": "What is the level of evidence for not recommending further testing for patients with a low risk of perioperative MACE?", "expected_output": "Level of Evidence: B"}, {"question": "What type of surgery is associated with the highest perioperative risk of MACE?", "expected_output": "Operations for peripheral vascular disease."}, {"question": "What tool is used to assess perioperative risk of major cardiac complications?", "expected_output": "The RCRI (Revised Cardiac Risk Index)."}, {"question": "How many predictors of risk does the RCRI include?", "expected_output": "6 predictors of risk."}, {"question": "What is the primary purpose of the American College of Surgeons NSQIP Surgical Risk Calculator?", "expected_output": "To enable procedure-specific risk assessment for a diverse group of outcomes."}, {"question": "What is the significance of functional status in perioperative cardiac events?", "expected_output": "Functional status is a reliable predictor of perioperative and long-term cardiac events, with reduced functional status preoperatively indicating increased risk of complications."}, {"question": "How is functional capacity expressed in the context of the document?", "expected_output": "Functional capacity is expressed in terms of metabolic equivalents (METs), where 1 MET is the resting or basal oxygen consumption of a 40-year-old, 70-kg man."}, {"question": "What activities are associated with a functional capacity of less than 4 METs?", "expected_output": "Activities associated with <4 METs include slow ballroom dancing, golfing with a cart, playing a musical instrument, and walking at approximately 2 mph to 3 mph."}, {"question": "What is the recommendation regarding preoperative resting 12-lead electrocardiograms (ECGs) for patients with known coronary heart disease?", "expected_output": "A preoperative resting 12-lead ECG is reasonable for patients with known coronary heart disease, significant arrhythmia, peripheral arterial disease, cerebrovascular disease, or other significant structural heart disease, except for those undergoing low-risk surgery."}, {"question": "What does the Duke Activity Status Index (DASI) measure?", "expected_output": "The Duke Activity Status Index (DASI) measures functional status based on the ability to perform various activities, assigning weights to each activity to assess overall functional capacity."}, {"question": "What is the first step in the stepwise approach to perioperative cardiac assessment for CAD?", "expected_output": "Determine the urgency of surgery."}, {"question": "What should be done if a patient has an acute coronary syndrome (ACS) during the perioperative assessment?", "expected_output": "Refer the patient for cardiology evaluation and management according to GDMT."}, {"question": "What risk calculator can be used to estimate the perioperative risk of major adverse cardiac events (MACE)?", "expected_output": "The American College of Surgeons NSQIP risk calculator."}, {"question": "What is the threshold for functional capacity below which further testing may be considered?", "expected_output": "Poor functional capacity is defined as less than 4 METs."}, {"question": "What does GDMT stand for in the context of this guideline?", "expected_output": "Guideline-directed medical therapy."}, {"question": "What is the Class III recommendation regarding routine preoperative resting 12-lead ECG for asymptomatic patients?", "expected_output": "Routine preoperative resting 12-lead ECG is not useful for asymptomatic patients undergoing low-risk surgical procedures."}, {"question": "What factors increase the value of the preoperative 12-lead ECG?", "expected_output": "The value of the preoperative 12-lead ECG is likely to increase with the risk of the surgical procedure, particularly for patients with known coronary heart disease, arrhythmias, peripheral arterial disease, cerebrovascular disease, or other significant structural heart disease."}, {"question": "What is the recommendation for preoperative evaluation of LV function in patients with dyspnea of unknown origin?", "expected_output": "It is reasonable for patients with dyspnea of unknown origin to undergo preoperative evaluation of LV function."}, {"question": "What is the recommendation regarding routine screening with noninvasive stress testing for low-risk noncardiac surgery?", "expected_output": "Routine screening with noninvasive stress testing is not useful for low-risk noncardiac surgery."}, {"question": "What does the acronym DSE stand for in the context of preoperative evaluations?", "expected_output": "DSE stands for dobutamine stress echocardiogram."}, {"question": "What is the recommended interval for stable patients according to Fleisher et al 2014 ACC/AHA Perioperative Guideline?", "expected_output": "1 to 3 months."}, {"question": "What is the level of evidence for the recommendation that it is reasonable for patients with dyspnea of unknown origin to undergo preoperative evaluation of LV function?", "expected_output": "Level of Evidence: C."}, {"question": "What LVEF percentage at rest is associated with the greatest risk of perioperative complications?", "expected_output": "LVEF at rest <35%."}, {"question": "What is the recommendation regarding routine preoperative evaluation of LV function?", "expected_output": "Routine preoperative evaluation of LV function is not recommended."}, {"question": "For patients with elevated risk and excellent functional capacity, what is the recommendation regarding further exercise testing?", "expected_output": "It is reasonable to forgo further exercise testing with cardiac imaging and proceed to surgery."}, {"question": "What is the proposed optimal anaerobic threshold for predicting perioperative cardiovascular complications?", "expected_output": "Approximately 10 mL O2/kg/min."}, {"question": "What type of surgery settings have cardiopulmonary exercise testing been studied in?", "expected_output": "Abdominal aortic aneurysm surgery, major abdominal surgery, hepatobiliary surgery, complex hepatic resection, lung resection, and colorectal, bladder, or kidney cancer surgery."}, {"question": "What is the recommendation for patients with poor functional capacity (<4 METs) before noncardiac surgery?", "expected_output": "It is reasonable for them to undergo noninvasive pharmacological stress testing if it will change management."}, {"question": "What does a normal study for perioperative MI and/or cardiac death indicate?", "expected_output": "It has a very high negative predictive value."}, {"question": "What is the significance of moderate to large areas of myocardial ischemia in preoperative evaluations?", "expected_output": "They are associated with increased risk of perioperative myocardial infarction (MI) and/or death."}, {"question": "What does a reversible myocardial perfusion defect predict according to the document?", "expected_output": "Perioperative events."}, {"question": "What is the reported range of positive test results for Dobutamine Stress Echocardiography (DSE)?", "expected_output": "5% to 50%."}, {"question": "What is the negative predictive value of DSE typically reported to be?", "expected_output": "90% to 100%."}, {"question": "What type of surgery has DSE predominantly evaluated for preoperative risk assessment?", "expected_output": "Abdominal aortic or peripheral vascular surgery."}, {"question": "Is routine preoperative coronary angiography recommended according to the document?", "expected_output": "No, it is not recommended."}, {"question": "What is the recommended timing for elective noncardiac surgery after balloon angioplasty?", "expected_output": "Elective noncardiac surgery should be delayed 14 days after balloon angioplasty."}, {"question": "What level of evidence supports the recommendation against routine coronary revascularization before noncardiac surgery to reduce perioperative cardiac events?", "expected_output": "Level of Evidence: B."}, {"question": "What are the two specific patient conditions under which preoperative PCI may be considered?", "expected_output": "1) Patients with left main disease whose comorbidities preclude bypass surgery without undue risk; 2) Patients with unstable CAD who would be appropriate candidates for emergency or urgent revascularization."}, {"question": "According to the document, how long should elective noncardiac surgery be delayed after drug-eluting stent (DES) implantation?", "expected_output": "Elective noncardiac surgery should optimally be delayed 365 days after drug-eluting stent (DES) implantation."}, {"question": "What is the recommendation regarding elective noncardiac surgery within 30 days after bare-metal stent (BMS) implantation?", "expected_output": "Elective noncardiac surgery should not be performed within 30 days after BMS implantation in patients in whom dual antiplatelet therapy (DAPT) will need to be discontinued perioperatively."}, {"question": "What is the recommendation for coronary revascularization before noncardiac surgery according to the guidelines?", "expected_output": "Revascularization before noncardiac surgery is recommended when indicated by existing CPGs."}, {"question": "How long should elective noncardiac surgery be delayed after balloon angioplasty?", "expected_output": "Elective noncardiac surgery should be delayed for 14 days after balloon angioplasty."}, {"question": "What is the class of recommendation (COR) for continuing beta blockers in patients who are on them chronically?", "expected_output": "I"}, {"question": "What is the recommendation regarding the initiation of statins in patients undergoing vascular surgery?", "expected_output": "Perioperative initiation of statin use is reasonable in patients undergoing vascular surgery."}, {"question": "What should be done with ACE inhibitors or ARBs if they are held before surgery?", "expected_output": "It is reasonable to restart ACE inhibitors or ARBs as soon as clinically feasible postoperatively."}, {"question": "What is the recommended therapy for patients undergoing noncardiac surgery who have been on beta blockers chronically?", "expected_output": "Beta blockers should be continued."}, {"question": "What is the risk associated with the preoperative administration of beta blockers according to the systematic review?", "expected_output": "Adverse outcomes such as bradycardia and stroke."}, {"question": "What is the time frame mentioned for considering PCI with DES and prolonged aspirin therapy if noncardiac surgery can be delayed?", "expected_output": "\u226512 months."}, {"question": "What should be considered if the noncardiac surgery is urgent or an emergency?", "expected_output": "The risks of ischemia and bleeding, and the long-term benefit of coronary revascularization must be weighed."}, {"question": "According to the document, what is the Class of Recommendation for continuing aspirin in patients undergoing nonemergency/nonurgent noncardiac surgery without prior coronary stenting?", "expected_output": "IIb."}, {"question": "What is the recommended management of beta blockers after surgery according to the document?", "expected_output": "Management should be guided by clinical circumstances, independent of when the agent was started."}, {"question": "What level of evidence supports the recommendation for continuing beta blockers in patients undergoing surgery?", "expected_output": "Level of Evidence B."}, {"question": "What is the recommendation regarding starting beta blockers on the day of surgery?", "expected_output": "Beta-blocker therapy should not be started on the day of surgery."}, {"question": "In patients with 3 or more RCRI risk factors, what is the recommendation regarding beta blockers before surgery?", "expected_output": "It may be reasonable to begin beta blockers before surgery."}, {"question": "What is the suggested time frame for initiating beta blockers before surgery to assess safety and tolerability?", "expected_output": "Preferably more than 1 day before surgery."}, {"question": "What is the main finding of the POISE study regarding beta blockers?", "expected_output": "The POISE study suggested that use of beta blockers reduced risks for cardiac events but produced a higher overall risk, largely related to stroke and higher rates of death from non-cardiac complications."}, {"question": "What was criticized about the POISE study's methodology?", "expected_output": "The POISE study was criticized for its use of a high dose of long-acting beta blocker and for initiating the dose immediately before noncardiac surgery."}, {"question": "What recommendation is given regarding the withdrawal of beta blockers in the perioperative period?", "expected_output": "The recommendation is that abrupt withdrawal of long-term beta blockers is harmful, providing a rationale for the ACC/AHA Class I recommendation."}, {"question": "What is the Class I recommendation regarding statin therapy for patients scheduled for noncardiac surgery?", "expected_output": "Statins should be continued in patients currently taking statins and scheduled for noncardiac surgery."}, {"question": "What does the evidence suggest about the risks associated with perioperative beta blockers?", "expected_output": "The evidence suggests that while perioperative beta blockers can reduce cardiac events, they are associated with a higher relative risk for perioperative strokes and uncertain mortality benefit or risk."}, {"question": "What percentage of participants died within 30 days of surgery according to the document?", "expected_output": "6.7%"}, {"question": "How many participants in the control group died within 30 days of surgery?", "expected_output": "10 of 73 (13.7%)"}, {"question": "What was the significant finding regarding statin use in patients undergoing noncardiac surgery?", "expected_output": "Statin use suggests a protective effect on cardiac complications."}, {"question": "What was the relative risk reduction of 30-day all-cause death for patients on statin therapy compared to nonusers?", "expected_output": "5-fold reduced risk"}, {"question": "What is the recommendation class for the use of alpha-2 agonists in preventing cardiac events during noncardiac surgery?", "expected_output": "Class III: No Benefit"}, {"question": "What percentage of patients in the study were on ACE inhibitors?", "expected_output": "13%"}, {"question": "What was the main finding regarding intraoperative ACE inhibitor users?", "expected_output": "They had more frequent transient intraoperative hypotension but no difference in other outcomes."}, {"question": "What combination of medications was associated with better postoperative outcomes in high-risk patients undergoing major vascular surgery?", "expected_output": "The combination of aspirin, beta blockers, and statins."}, {"question": "What is the recommendation for patients undergoing urgent noncardiac surgery within the first 4 to 6 weeks after stent implantation?", "expected_output": "DAPT should be continued unless the relative risk of bleeding outweighs the benefit of preventing stent thrombosis."}, {"question": "What does the document suggest about the evidence for the harms of ARBs compared to ACE inhibitors?", "expected_output": "Data describing harms of ARBs are sparse, but treating such drugs as equivalent to ACE inhibitors is reasonable."}, {"question": "What was the association found with aspirin use during the perioperative period?", "expected_output": "Aspirin use was associated with an increased risk of major bleeding."}, {"question": "In the POISE-2 trial, how many days before surgery was aspirin typically stopped?", "expected_output": "Aspirin was usually stopped 7 days pre-operatively."}, {"question": "What percentage of the study population had known prior CAD?", "expected_output": "23% of the study population had known prior CAD."}, {"question": "What types of patients were excluded from the POISE-2 trial?", "expected_output": "Patients within 6 weeks of placement of a BMS or within 1 year of placement of a DES were excluded."}, {"question": "What is generally discouraged regarding the use of anticoagulants during the perioperative period?", "expected_output": "The use of therapeutic or full-dose anticoagulants is generally discouraged."}, {"question": "What are the examples of alternative anticoagulants mentioned in the document?", "expected_output": "Factor Xa inhibitors and direct thrombin inhibitors."}, {"question": "For what purpose are vitamin K antagonists like warfarin prescribed?", "expected_output": "For stroke prevention in patients with AF, prevention of thrombotic and thromboembolic complications in patients with prosthetic valves, and in patients requiring deep venous thrombosis prophylaxis and treatment."}, {"question": "What is the recommended action for patients with AF and normal renal function undergoing elective procedures?", "expected_output": "Discontinuation of anticoagulants for \u226548 hours."}, {"question": "What is the peak incidence period for postoperative AF after surgery?", "expected_output": "1 to 3 days postoperatively."}, {"question": "What treatment is generally used for ventricular rate control in acute postoperative AF?", "expected_output": "Beta blockers or nondihydropyridine calcium channel blockers (i.e., diltiazem or verapamil)."}, {"question": "What medications can be used to terminate recurrent supraventricular tachycardia?", "expected_output": "Vagal maneuvers, adenosine, or verapamil."}, {"question": "What should be avoided in the setting of pre-excited atrial fibrillation?", "expected_output": "Digoxin and calcium channel blockers."}, {"question": "What is the recommended treatment for symptomatic or hemodynamically compromising ventricular ectopy?", "expected_output": "Antiarrhythmic therapy."}, {"question": "What is the primary concern regarding the interaction between CIEDs and electrocautery?", "expected_output": "Transient inhibition of pacing in pacemaker-dependent patients and inappropriate triggering of shocks in patients with ICDs."}, {"question": "What should be ensured before the discharge of patients with ICDs who had preoperative reprogramming?", "expected_output": "That tachytherapy has been restored."}, {"question": "What is the main concern regarding inactivated ICDs during the perioperative period?", "expected_output": "At least 3 deaths have been reported to have been caused by failure to reactivate ICD tachytherapies in patients who had ICD therapy inactivated preoperatively."}, {"question": "What are the four main classifications of anesthesia mentioned in the document?", "expected_output": "Local anesthesia, regional anesthesia, monitored anesthesia care, and general anesthesia."}, {"question": "What does the 2011 Cochrane review meta-analysis reveal about myocardial infarction rates in neuraxial versus general anesthesia?", "expected_output": "The meta-analysis found an overall 4% MI rate in both groups."}, {"question": "What is the recommendation regarding the use of prophylactic intravenous nitroglycerin during noncardiac surgery?", "expected_output": "Prophylactic intravenous nitroglycerin is not effective in reducing myocardial ischemia in patients undergoing noncardiac surgery."}, {"question": "What is the significance of maintaining normothermia during surgery according to the recommendations?", "expected_output": "Maintenance of normothermia may be reasonable to reduce perioperative cardiac events."}, {"question": "What is the main finding regarding the use of volatile anesthesia compared to total intravenous anesthesia in noncardiac surgery?", "expected_output": "There is no evidence to suggest a difference in myocardial ischemia/MI rates between the use of volatile anesthesia and total intravenous anesthesia."}, {"question": "What type of anesthesia is recommended for postoperative pain relief in patients undergoing abdominal aortic surgery?", "expected_output": "Neuraxial anesthesia."}, {"question": "What was the event MI rate in the meta-analysis of over 79 studies comparing volatile anesthesia and total intravenous anesthesia?", "expected_output": "0 for both groups."}, {"question": "What is the recommendation regarding the use of prophylactic intravenous nitroglycerin in patients undergoing noncardiac surgery?", "expected_output": "Prophylactic intravenous nitroglycerin is not effective in reducing myocardial ischemia."}, {"question": "What does the document state about the routine use of intraoperative transesophageal echocardiogram (TEE) during non-cardiac surgery?", "expected_output": "The routine use of intraoperative TEE to screen for cardiac abnormalities or to monitor for myocardial ischemia is not recommended in patients without risk factors."}, {"question": "What is the recommendation regarding the use of intraoperative TEE in patients undergoing non-cardiac surgery?", "expected_output": "The data are insufficient in terms of predictive accuracy or cost-effectiveness to recommend routine TEE monitoring."}, {"question": "What complications are associated with hypothermia during the perioperative period?", "expected_output": "Wound infection, MACE, immune dysfunction, coagulopathy, increased blood loss, death, and transfusion requirements."}, {"question": "What is the 30-day mortality rate range for patients with mechanical circulatory support undergoing noncardiac procedures?", "expected_output": "The 30-day mortality rate ranges from 9% to 25%."}, {"question": "What is the class recommendation for the routine use of pulmonary artery catheterization in patients at elevated surgical risk?", "expected_output": "Routine use of pulmonary artery catheterization in patients at elevated surgical risk is not recommended."}, {"question": "Which organizations developed CPGs for the appropriate use of TEE?", "expected_output": "The American Society of Anesthesiologists, the Society of Cardiovascular Anesthesiologists, and the American Society of Echocardiography."}, {"question": "What is the hemoglobin level threshold for a liberal transfusion strategy in the 2011 RCT?", "expected_output": "Hemoglobin <10 g/dL."}, {"question": "What does the 2012 American Association of Blood Banks CPG recommend for asymptomatic, hemodynamically stable patients without CAD?", "expected_output": "A restricted transfusion strategy (hemoglobin <7 g/dL to 8 g/dL)."}, {"question": "What is the recommended maintenance hemoglobin concentration for postoperative patients?", "expected_output": "\u22658 g/dL, unless the patient exhibits symptoms."}, {"question": "What is the Class I recommendation regarding troponin levels in patients with signs or symptoms suggestive of myocardial ischemia or MI?", "expected_output": "Measurement of troponin levels is recommended."}, {"question": "In the VISION trial, what did elevations of troponin predict?", "expected_output": "Elevations of troponin predicted vascular and nonvascular mortality rates."}, {"question": "What is the purpose of the MANAGE trial mentioned in the document?", "expected_output": "To test the effects of dabigatran and omeprazole in preventing death, major cardiovascular complications, and major upper gastrointestinal bleeding in patients who have had myocardial injury after noncardiac surgery."}, {"question": "What percentage of vascular surgery patients had elevated troponin levels according to the study referenced?", "expected_output": "Forty percent."}, {"question": "What are the four areas of focus for future research directions as outlined in the document?", "expected_output": "Surveillance, Discovery, Translation, Dissemination."}, {"question": "What has been the relative reduction in risk-adjusted mortality rates for major cancer surgery over the past decade?", "expected_output": "11% to 19%."}, {"question": "What is the current stance on the use of postoperative electrocardiography according to the document?", "expected_output": "The role of postoperative electrocardiography remains difficult to define and cannot be recommended for routine use due to insufficient clinical trial data."}, {"question": "What is the main approach needed to implement the recommendations of the current perioperative CPGs effectively?", "expected_output": "A 'perioperative team approach' is needed."}, {"question": "Who are the members of the perioperative team mentioned in the document?", "expected_output": "The members include the patient and family, surgeon, anesthesiologist, cardiologist, hospitalist, primary care clinician, and additional clinicians depending on the patient's unique circumstances."}, {"question": "What is the goal of shared decision making in the perioperative context?", "expected_output": "To take into account the patient\u2019s preferences, values, and goals."}, {"question": "Who is the President of the American College of Cardiology as mentioned in the document?", "expected_output": "Patrick T. O\u2019Gara, MD, MACC."}, {"question": "What type of future research is suggested in the document?", "expected_output": "Research to understand how information on perioperative risk is incorporated into patient decision making."}, {"question": "What is the title of the 2011 guideline for the diagnosis and treatment of hypertrophic cardiomyopathy?", "expected_output": "2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary."}, {"question": "Which organizations collaborated on the 2005 guidelines for the management of patients with peripheral arterial disease?", "expected_output": "American Association for Vascular Surgery, Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines."}, {"question": "In what year was the guideline for coronary artery bypass graft surgery published?", "expected_output": "2011."}, {"question": "What is the focus of the practice advisory for preanesthesia evaluation updated in 2012?", "expected_output": "An updated report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation."}, {"question": "What is the main topic of the consensus statement by the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists published in 2013?", "expected_output": "Basic perioperative transesophageal echocardiography examination."}, {"question": "What year was the ACC/AHA Perioperative Guideline by Fleisher et al. published?", "expected_output": "2014"}, {"question": "Which journal published the meta-analysis on adverse cardiac events by Fleisher et al.?", "expected_output": "J Am Coll Cardiol"}, {"question": "What is the focus of the systematic review conducted by Karthikeyan et al.?", "expected_output": "The independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery."}, {"question": "What is the main finding of the study by Rajagopalan et al. regarding N-terminal pro B-type natriuretic peptide?", "expected_output": "It is an independent predictor of postoperative myocardial injury in patients undergoing major vascular surgery."}, {"question": "What type of surgery is discussed in the context of the prognostic value of brain natriuretic peptide according to Rodseth et al.?", "expected_output": "Noncardiac surgery"}, {"question": "What is the title of the article authored by Ammash NM et al.?", "expected_output": "Noncardiac surgery in Eisenmenger syndrome."}, {"question": "In which journal was the article by Christensen RE et al. published in 2010?", "expected_output": "British Journal of Anaesthesia."}, {"question": "What year was the ACS NSQIP Surgical Risk Calculator published?", "expected_output": "2013."}, {"question": "Which study discusses the predictive value of preoperative electrocardiography for perioperative cardiovascular outcomes?", "expected_output": "Predictive value of preoperative electrocardiography for perioperative cardiovascular outcomes in patients undergoing noncardiac, nonvascular surgery."}, {"question": "What is the main focus of the article by Goei D et al. published in 2009?", "expected_output": "Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients."}, {"question": "What year was the study by Poldermans et al. on dobutamine stress echocardiography published?", "expected_output": "1993"}, {"question": "Which journal published the meta-analysis comparing the prognostic accuracy of six diagnostic tests for predicting perioperative cardiac risk?", "expected_output": "Heart"}, {"question": "What is the main focus of the study conducted by Hartley et al. in 2012?", "expected_output": "Preoperative cardiopulmonary exercise testing and risk of early mortality following abdominal aortic aneurysm repair."}, {"question": "Which imaging technique was assessed by Cohen et al. in 2003 for its prognostic value in patients evaluated for elective vascular surgery?", "expected_output": "Dipyridamole Tc-99m sestamibi myocardial tomography."}, {"question": "What was the conclusion of the study by Brown and Rowen regarding myocardial perfusion imaging?", "expected_output": "It best predicts perioperative cardiac events in patients undergoing noncardiac surgery."}, {"question": "What is the primary focus of the studies referenced in the document?", "expected_output": "The studies focus on the use of dobutamine stress echocardiography for cardiac risk assessment in patients undergoing various types of surgery."}, {"question": "In which year was the study by Langan EM et al. published?", "expected_output": "1993."}, {"question": "What was the conclusion of the study by Raux M et al. regarding dobutamine stress echocardiography?", "expected_output": "The study concluded that there is a low negative predictive value of dobutamine stress echocardiography before abdominal aortic surgery."}, {"question": "Which journal published the study by Poldermans D et al. on improved cardiac risk stratification?", "expected_output": "J Am Coll Cardiol."}, {"question": "What is the significance of the POISE trial mentioned in the document?", "expected_output": "The POISE trial is significant as it evaluates the effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery."}, {"question": "What is the title of the study by Brooke BS et al. mentioned in the document?", "expected_output": "Use of beta-blockers during aortic aneurysm repair: bridging the gap between evidence and effective practice."}, {"question": "In which year was the study by Poldermans D et al. published?", "expected_output": "1999."}, {"question": "What is the main focus of the study by Wijeysundera DN et al. published in 2014?", "expected_output": "Duration of pre-operative beta-blockade and outcomes after major elective non-cardiac surgery."}, {"question": "Which beta-blocker was associated with reduced mortality compared to metoprolol according to Wallace AW et al. in 2011?", "expected_output": "Atenolol."}, {"question": "What type of surgery is the focus of the meta-analysis conducted by Devereaux PJ et al. in 2005?", "expected_output": "Non-cardiac surgery."}, {"question": "What is the title of the article authored by Lau WC et al.?", "expected_output": "Impact of adding aspirin to beta-blocker and statin in high-risk patients undergoing major vascular surgery."}, {"question": "In which journal was the article by Stone NJ et al. published?", "expected_output": "Circulation."}, {"question": "What year was the ACC/AHA guideline on the treatment of blood cholesterol published?", "expected_output": "2013."}, {"question": "What is the main focus of the study conducted by Reddy PR and Vaitkus PT?", "expected_output": "Risks of noncardiac surgery after coronary stenting."}, {"question": "Which anesthetic agent was found to provide greater protection of the myocardium than propofol in patients undergoing off-pump coronary artery bypass surgery?", "expected_output": "Sevoflurane."}, {"question": "What is the title of the guideline authored by Fleisher et al. in 2014?", "expected_output": "2014 ACC/AHA Perioperative Guideline"}, {"question": "Which study concluded that epidural analgesia reduces postoperative myocardial infarction?", "expected_output": "A meta-analysis by Beattie WS, Badner NH, Choi P published in Anesth Analg in 2001."}, {"question": "What was the focus of the study by Frank SM et al. published in JAMA in 1997?", "expected_output": "The perioperative maintenance of normothermia to reduce the incidence of morbid cardiac events."}, {"question": "Which trial assessed the effectiveness of pulmonary artery catheters in high-risk surgical patients?", "expected_output": "A randomized, controlled trial published in N Engl J Med in 2003."}, {"question": "What is the significance of the 2013 International Society for Heart and Lung Transplantation Guidelines?", "expected_output": "They provide an executive summary for mechanical circulatory support."}, {"question": "What is the publication date of the Circulation journal referenced in the document?", "expected_output": "December 9/16, 2014."}, {"question": "Which societies are mentioned in the document excerpt?", "expected_output": "Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine, and Society for Vascular Surgery."}, {"question": "What is the title of the study conducted by Lim W et al. as referenced in the document?", "expected_output": "The diagnosis of myocardial infarction in critically ill patients: an agreement study."}, {"question": "In which journal was the systematic review and meta-analysis by Chopra V et al. published?", "expected_output": "Arch Surg."}, {"question": "What is the focus of the study by Finks JF et al. mentioned in the document?", "expected_output": "Trends in hospital volume and operative mortality for high-risk surgery."}, {"question": "What year was the ACC/AHA Perioperative Guideline by Fleisher et al. published?", "expected_output": "2014"}, {"question": "Which study compared coronary artery bypass surgery and percutaneous drug-eluting stent implantation for left main coronary artery stenosis?", "expected_output": "Comparison of coronary artery bypass surgery and percutaneous drug-eluting stent implantation for treatment of left main coronary artery stenosis."}, {"question": "What is the main focus of the study by Park S-J et al. published in 2011?", "expected_output": "Randomized trial of stents versus bypass surgery for left main coronary artery disease."}, {"question": "Which publication discusses the long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty?", "expected_output": "Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease."}, {"question": "What is the significance of the study by Hannan EL et al. published in 2005?", "expected_output": "Long-term outcomes of coronary-artery bypass grafting versus stent implantation."}, {"question": "Who is the Chair of the committee mentioned in the document?", "expected_output": "Lee A. Fleisher."}, {"question": "What position does Kirsten E. Fleischmann hold?", "expected_output": "Professor of Clinical Medicine at UCSF School of Medicine, Division of Cardiology."}, {"question": "Which institution is associated with Andrew D. Auerbach?", "expected_output": "UCSF Division of Hospital Medicine."}, {"question": "What financial relationships does Joshua A. Beckman have?", "expected_output": "He has relationships with AstraZeneca, Bristol-Myers Squibb, Novartis, Merck, and Boston Scientific."}, {"question": "What is the role of Biykem Bozkurt at the Baylor College of Medicine?", "expected_output": "The Mary and Gordon Cain Chair, Professor of Medicine, and Director of the Winters Center for Heart Failure Research."}, {"question": "What is the role of Joseph E. Marine at Johns Hopkins University?", "expected_output": "Associate Professor of Medicine; Associate Director of Electrophysiology; Associate Division Chief of Cardiology."}, {"question": "Which institution is Duminda N. Wijeysundera affiliated with as a scientist?", "expected_output": "Li Ka Shing Knowledge Institute of St. Michael\u2019s Hospital."}, {"question": "What is the threshold for a person to be deemed to have a significant interest in a business according to the document?", "expected_output": "Ownership of \u22655% of the voting stock or share of the business entity, or ownership of \u2265$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person\u2019s gross income for the previous year."}, {"question": "What is the requirement for writing committee members regarding voting on sections related to their industry relationships?", "expected_output": "Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply."}, {"question": "What does ACC/AHA stand for?", "expected_output": "American College of Cardiology; American Heart Association."}, {"question": "What is the title of the guideline discussed in the document?", "expected_output": "2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery"}, {"question": "Who is the official reviewer from the University of Michigan Health System?", "expected_output": "Kim Eagle"}, {"question": "Which organization is associated with Dipti Itchhaporia?", "expected_output": "ACC Board of Trustees"}, {"question": "What position does Frank W. Sellke hold at Brown Medical School?", "expected_output": "Professor; Chief of Cardiothoracic Surgery"}, {"question": "Which company is listed as a financial benefit for G. B. John Mancini?", "expected_output": "Merck"}, {"question": "What is the role of Rupa Mehta Sanghani as mentioned in the document?", "expected_output": "Organizational Reviewer\u2014ASNC at University of Chicago Medicine, Director of Cardiac Rehabilitation, Assistant Professor of Medicine."}, {"question": "Which hospital is Reena Pande associated with?", "expected_output": "Brigham and Women\u2019s Hospital."}, {"question": "What financial relationships does Jeanne Poole have according to the document?", "expected_output": "She has relationships with Biotronik, Boston Scientific, Medtronic, and St. Jude Medical."}, {"question": "What position does Russell Postier hold at the University of Oklahoma Health Sciences Center?", "expected_output": "John A. Schilling Professor and Chairman, Department of Surgery."}, {"question": "Which company is associated with Steven Cohn as a defendant in a legal matter?", "expected_output": "Defendant in venous thromboemboli pulmonary embolism, 2013 and preoperative evaluation, 2013."}, {"question": "What is the role of George Crossley as mentioned in the document?", "expected_output": "Content Reviewer\u2014ACC Electro-physiology Section Leadership Council and Medical Director, Cardiac Services at St. Thomas Heart."}, {"question": "Which institution is P.J. Devereaux associated with?", "expected_output": "McMaster University."}, {"question": "What type of financial benefits does Richard Lange have according to the document?", "expected_output": "None."}, {"question": "What position does Maria Lantin-Hermoso hold at Baylor College of Medicine?", "expected_output": "Associate Professor, Department of Pediatrics, Section of Cardiology."}, {"question": "Which companies are associated with E. Magnus Ohman as mentioned in the document?", "expected_output": "Abiomed, AstraZeneca, Daiichi-Sankyo, Gilead Sciences, Janssen Pharmaceuticals, Pozen, Sanofi-aventis, The Medicines Company."}, {"question": "What position does Gurusher Panjrath hold at the George Washington Heart and Vascular Institute?", "expected_output": "Assistant Professor of Medicine; Director, Heart Failure and Mechanical Support Program."}, {"question": "Which university is Susan J. Pressler affiliated with?", "expected_output": "University of Michigan School of Nursing."}, {"question": "What is the role of Pasala Ravichandran at Oregon Health and Science University?", "expected_output": "Associate Professor."}, {"question": "Which pharmaceutical company is John Erwin associated with as a principal investigator?", "expected_output": "Eli Lilly."}, {"question": "What is Samuel Gidding's position at Nemours/Alfred I. DuPont Hospital for Children?", "expected_output": "Chief, Division of Pediatric Cardiology."}, {"question": "What is the title of Ralph Verdino's position at the Hospital of the University of Pennsylvania?", "expected_output": "Associate Professor of Medicine; Director, Cardiology Electrophysiology Fellowship Program."}, {"question": "Which companies are associated with Ralph Verdino as per the document?", "expected_output": "Biotronik, Medtronic, St. Jude Medical."}, {"question": "What is the definition of a significant interest in a business according to the document?", "expected_output": "Ownership of \u22655% of the voting stock or share of the business entity, or ownership of \u2265$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person\u2019s gross income for the previous year."}, {"question": "What does ACC stand for as mentioned in the document?", "expected_output": "American College of Cardiology."}, {"question": "How are the names of reviewers listed in the document?", "expected_output": "In alphabetical order within each category of review."}, {"question": "What is the recommended approach for UPLM or complex CAD according to the guidelines?", "expected_output": "Heart Team approach recommended."}, {"question": "What is the Class of Recommendation (COR) for CABG in patients with UPLM?", "expected_output": "I."}, {"question": "What is the significance of a low SYNTAX score in the context of PCI for SIHD?", "expected_output": "A low SYNTAX score of \u226422 indicates a high likelihood of good long-term outcome."}, {"question": "What does the recommendation IIb indicate for PCI in patients with 3-vessel disease?", "expected_output": "Of uncertain benefit."}, {"question": "What is the COR for CABG in patients with 1-vessel disease without proximal LAD artery involvement?", "expected_output": "III: Harm."}, {"question": "What is the Class of Recommendation for CABG in patients with LV dysfunction and EF between 35% to 50%?", "expected_output": "IIa"}, {"question": "What is the Level of Evidence for the recommendation of beta-blocker therapy in all patients with LV systolic dysfunction (EF \u226440%) with HF or prior MI?", "expected_output": "A"}, {"question": "What does CABG stand for as mentioned in the document?", "expected_output": "Coronary artery bypass graft"}, {"question": "Which beta-blockers are recommended for use in patients with LV systolic dysfunction according to the document?", "expected_output": "Carvedilol, metoprolol succinate, or bisoprolol"}, {"question": "What is the recommendation for beta-blocker therapy in patients with normal LV function who have had MI or ACS?", "expected_output": "It should be started and continued for 3 years."}, {"question": "What does the abbreviation 'ACE' stand for?", "expected_output": "angiotensin-converting enzyme"}, {"question": "What is the meaning of the abbreviation 'CABG'?", "expected_output": "coronary artery bypass graft"}, {"question": "What does 'DAPT' refer to in the context of the document?", "expected_output": "dual antiplatelet therapy"}, {"question": "What is the full form of the abbreviation 'TAVR'?", "expected_output": "transcatheter aortic valve replacement"}, {"question": "What does 'MACE' stand for?", "expected_output": "major adverse cardiac event"}]